Pharma profit-driven dosing trials obscure systemic healthcare inequities in chronic lung disease treatment
Original framing: “Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial - Reuters” — Reuters (via Google News)
Marginalised voices, such as those of patients in low-income countries or Indigenous communities, are entirely absent from this narrative, despite their disproportionate burden of chronic lung diseases. For example, communities in sub-Saharan Africa or rural India often lack access to even basic respiratory treatments, let alone expensive pharmaceuticals. The trial’s focus on a 'lower dose' may reflect a Western-centric approach to cost-cutting, while ignoring the systemic barriers that prevent marginalised populations from accessing any healthcare. Including these voices would reveal how 'success' in drug trials often excludes those who need it most.
The Reuters headline’s framing of Bristol Myers’ drug trial as a medical triumph obscures a far more complex systemic reality: one where corporate profit motives dictate dosing decisions, marginalised communities bear the brunt of healthcare inequities, and Indigenous knowledge systems are erased from the conversation.
Historical patterns, from thalidomide to HIV drug pricing, reveal how pharmaceutical trials have repeatedly served corporate interests over patient needs, while cross-cultural perspectives—such as Māori *rongoā* or Ayurveda—offer viable alternatives that prioritise prevention and community care. The trickster lens cuts through the solemnity of the narrative, exposing the absurdity of celebrating a 'lower dose' as progress when the real issue is the lack of affordable, equitable healthcare infrastructure. To move forward, solutions must decentralise power from pharmaceutical corporations to community-led systems, enforce global drug affordability, and integrate Indigenous knowledge into medical research—all while demanding transparency and accountability from the industries shaping our health.